Stock RGBPP REGEN BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Regen BioPharma, Inc. OTC Markets

Equities

RGBPP

US75886M4096

Market Closed - OTC Markets
Other stock markets
 10:58:14 17/06/2024 pm IST 		5-day change 1st Jan Change
1.5 USD +48.51% Intraday chart for Regen BioPharma, Inc. 0.00% -36.40%
24/04 Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 CI
09/02 Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Regen BioPharma : Material Event - Form 8-K
PU
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
CI
Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells
CI
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024
PR
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
CI
Regen BioPharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023
CI
Regen BioPharma, Inc. Outlines Future Steps in CAR T Program
CI
Regen BioPharma, Inc Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program
CI
Regen Biopharma, Inc. Expects Second Phase of Confirmatory Study Shortly
CI
Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer
AQ
Studies on Regen Biopharma, Inc.'s Duracar Indicate Potential Suppression of Autoimmunity, Company Retains Contract Research Organization to Conduct Additional Confirmatory Studies
CI
Regen BioPharma, Inc. announced that it has received $0.14875 million in funding
CI
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on August 10, 2023
PR
Regen BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023
CI
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023
CI
REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)
AQ
Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio
AQ
REGEN BIOPHARMA INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)
AQ
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022
CI
Regen BioPharma, Inc. Announces Board Appointments
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RGBP Stock
  4. RGBPP Stock
  5. News Regen BioPharma, Inc.